Hepatitis C News and Research

Latest Hepatitis C News and Research

Isis Pharmaceuticals reports pro forma net operating loss of $22.6 million for Q1 2014

Isis Pharmaceuticals, Inc. today reported a pro forma net operating loss (NOL) of $22.6 million for the three months ended March 31, 2014 compared to pro forma operating income of $4.5 million for the same period in 2013.

6 May 2014

Nanoviricides develops new drug candidates against MERS infection

...

6 May 2014

Liver cancer screening in cirrhosis patients improves survival rates

Liver cancer survival rates could be improved if more people with cirrhosis are screened for tumors using inexpensive ultrasound scans and blood tests, according to a review by doctors at UT Southwestern Medical Center.

6 May 2014

Health spending increases hit fastest pace since 1980

USA Today reports on this development, noting some of the factors that will continue to drive up costs. Also, Kaiser Health News explores issues related to who should get costly hepatitis C drugs and The Wall Street Journal reports on the delay in implementing the ICD-10.

6 May 2014

Alcohol consumption linked with increased risk of advanced liver fibrosis in HIV patients

Consumption of alcohol has long been associated with an increased risk of advanced liver fibrosis, but a new study published online in Clinical Infectious Diseases from researchers at Penn Medicine and other institutions shows that association is drastically heightened in people co-infected with both HIV and chronic hepatitis C virus (HCV) infection.

5 May 2014

First Edition: May 5, 2014

Today's headlines include reports about how President Barack Obama poked fun at the health law during his White House Correspondents' Dinner speech.

5 May 2014

New webcast for hepatitis receives accreditation by RCN Centre

Roche: The ‘Confronting the silent epidemic: clinical innovation forum’ webcast endorsed by HCV Action, British Liver Trust and the European Liver Patients Association, is now available for healthcare professionals (HCPs) to view on-demand.

5 May 2014

Study: New combination therapy to treat chronic hepatitis C

A new combination therapy allows chronic hepatitis C to be treated in a manner that is less aggressive yet equally efficient.

5 May 2014

HealthHIV: Nearly 50% of primary care providers lack knowledge about HIV treatment

Primary care providers who provide clinical HIV care (HIV PCPs) are experiencing rising HIV caseloads from newly insured patients under the Patient Protection and Affordable Care Act (PPACA), according to a national survey released today by HealthHIV.

2 May 2014

Viewpoints: Boehner's 'truthful gaffe' on health law; Larry Kramer's AIDS crusade; costly drugs

Although "repeal and replace" has been the Republican position on Obamacare since 2010, "replace" has been there mainly because it polled well. Republicans were satisfied with the health-care status quo in 2009, and would have been glad to repeal Obamacare to return to it. As Steve Benen points out, Republicans voted for just-plain-repeal many times.

29 Apr 2014

Discovery offers potential target for reversing progression of end-stage liver disease

A team of researchers in the University of Arizona's College of Pharmacy has discovered a molecular pathway that could be key to creating new therapeutics that would slow or even reverse the progression of end-stage liver disease.

26 Apr 2014

Aetna raises earnings outlook

In other market news, coverage continues of the cost and effectiveness of Sovaldi, a new drug to treat hepatitis C, and the related earnings gained by Gilead Sciences, its manufacturer.

25 Apr 2014

First Edition: April 24, 2014

Today's headlines include a number of reports about how the health law is playing in midterm election campaigns.

25 Apr 2014

Sales of hepatitis drug shatter records

Record sales of the pricey new drug, Sovaldi, pushed first-quarter earnings of Gilead Sciences beyond expectations. Meanwhile, Novartis' recently announced deals with GlaxoSmithKline and Eli Lilly show manufacturers' swing towards specialization, reports The Wall Street Journal.

25 Apr 2014

First Edition: April 23, 2014

Today's headlines include a range of health policy news reports, including developments related to the health law, to the marketplace and at the state level.

23 Apr 2014

FDA announces expanded approval of Arzerra in combination with chlorambucil for CLL treatment

The US Food and Drug Administration has announced the expanded approval of Arzerra (ofatumumab) in combination with chlorambucil for the first-line treatment of chronic lymphocytic leukemia (CLL). Arzerra was previously approved by the FDA in October 2009 for the treatment of CLL resistant to other forms of chemotherapy. Diplomat has access to dispense Arzerra.

22 Apr 2014

Cost of Hep C medicines vexing insurers

As health insurance companies reveal much anticipated first-quarter earnings, it's the unpredictable impact from the five-figure cost of new Hepatitis C treatments that are the subject of as much Wall Street worry as the Affordable Care Act.

22 Apr 2014

Automated diagnostic technologies redefine infectious diseases

The diagnostics market for infectious diseases such as tuberculosis (TB), human immunodeficiency virus (HIV), hepatitis C virus and human papilloma virus is expanding, giving rise to commercial opportunities especially in the developing economies of Asia, Africa and Latin America.

22 Apr 2014

Doctors must consider factors when administering combination vaccines, say researchers

One of the most popular vaccine brands for children may not be the most cost-effective choice. And doctors may be overlooking some cost factors when choosing vaccines, driving the market toward what is actually a more expensive option, according to a new study by University of Illinois researchers.

22 Apr 2014

UnitedHealth cites health law, costly hepatitis drug in reporting lower earnings

The health law's effect was mixed, officials said, because the company did not participate in many of the online marketplaces, but it did see more customers for its Medicaid plans. Officials are considering a bigger role in the marketplaces next year.

21 Apr 2014

Hepatitis C News and Research

Latest Hepatitis C News and Research

Isis Pharmaceuticals reports pro forma net operating loss of $22.6 million for Q1 2014

Nanoviricides develops new drug candidates against MERS infection

Liver cancer screening in cirrhosis patients improves survival rates

Health spending increases hit fastest pace since 1980

Alcohol consumption linked with increased risk of advanced liver fibrosis in HIV patients

First Edition: May 5, 2014

New webcast for hepatitis receives accreditation by RCN Centre

Study: New combination therapy to treat chronic hepatitis C

HealthHIV: Nearly 50% of primary care providers lack knowledge about HIV treatment

Viewpoints: Boehner's 'truthful gaffe' on health law; Larry Kramer's AIDS crusade; costly drugs

Discovery offers potential target for reversing progression of end-stage liver disease

Aetna raises earnings outlook

First Edition: April 24, 2014

Sales of hepatitis drug shatter records

First Edition: April 23, 2014

FDA announces expanded approval of Arzerra in combination with chlorambucil for CLL treatment

Cost of Hep C medicines vexing insurers

Automated diagnostic technologies redefine infectious diseases

Doctors must consider factors when administering combination vaccines, say researchers

UnitedHealth cites health law, costly hepatitis drug in reporting lower earnings

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Hepatitis C News and Research

Latest Hepatitis C News and Research

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Newsletters you may be interested in